Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890230728> ?p ?o ?g. }
Showing items 1 to 100 of
100
with 100 items per page.
- W2890230728 endingPage "140" @default.
- W2890230728 startingPage "135" @default.
- W2890230728 abstract "Abstract Introduction Immune checkpoint inhibitors (ICIs) are standard therapies in advanced NSCLC. Although genotype-directed tyrosine kinase inhibitors represent the standard of care for subsets of oncogene-driven NSCLC, patients may receive ICIs during their disease course. The impact of sequential ICI and tyrosine kinase inhibitor therapy on the risk of hepatotoxicity has not been described. Methods Patients with advanced ALK receptor tyrosine kinase (ALK)-driven, ROS1-driven, or MET proto-oncogene, receptor tyrosine kinase (MET)-driven NSCLC treated with crizotinib, with or without preceding ICI therapy, were identified. The cumulative incidences of crizotinib-associated grade 3 or higher increases in transaminase level (per the Common Terminology Criteria for Adverse Events, version 4.0) were compared. Results We identified 453 patients who had NSCLC with an oncogenic alteration in ALK receptor tyrosine kinase gene (ALK), ROS1, or MET proto-oncogene, receptor tyrosine kinase gene (MET) and were treated with crizotinib (11 with and 442 without prior ICI therapy). Among the 11 patients treated with an ICI followed by crizotinib, five (cumulative incidence 45.5% [95% confidence interval (CI): 14.9–72.2]) experienced development of a grade 3 or 4 increase in alanine transaminase level and four (cumulative incidence 36.4% [95% CI: 10.0–64.2]) experienced development of a grade 3 or 4 increase in aspartate transaminase level. In comparison, among the 442 patients who received crizotinib only, a grade 3 or 4 increase in alanine transaminase level occurred in 34 patients (cumulative incidence 8.1% [95% CI: 5.7–11.0, p Conclusions Sequential ICI and crizotinib treatment is associated with a significantly increased risk of hepatotoxicity. Careful consideration and monitoring for hepatotoxicity may be warranted in patients treated with crizotinib after ICI therapy." @default.
- W2890230728 created "2018-09-27" @default.
- W2890230728 creator A5005314279 @default.
- W2890230728 creator A5005596596 @default.
- W2890230728 creator A5032331306 @default.
- W2890230728 creator A5037376490 @default.
- W2890230728 creator A5055464555 @default.
- W2890230728 creator A5064382279 @default.
- W2890230728 creator A5071789339 @default.
- W2890230728 creator A5072389805 @default.
- W2890230728 creator A5080311196 @default.
- W2890230728 creator A5081227348 @default.
- W2890230728 creator A5085217465 @default.
- W2890230728 date "2019-01-01" @default.
- W2890230728 modified "2023-10-18" @default.
- W2890230728 title "Increased Hepatotoxicity Associated with Sequential Immune Checkpoint Inhibitor and Crizotinib Therapy in Patients with Non–Small Cell Lung Cancer" @default.
- W2890230728 cites W1990626198 @default.
- W2890230728 cites W2050249255 @default.
- W2890230728 cites W2134787029 @default.
- W2890230728 cites W2286173468 @default.
- W2890230728 cites W2342296008 @default.
- W2890230728 cites W2527905628 @default.
- W2890230728 cites W2571208503 @default.
- W2890230728 cites W2643935873 @default.
- W2890230728 cites W2782465645 @default.
- W2890230728 cites W2782863308 @default.
- W2890230728 cites W2791886669 @default.
- W2890230728 cites W2796582438 @default.
- W2890230728 cites W2889653218 @default.
- W2890230728 cites W2890721204 @default.
- W2890230728 cites W2891004049 @default.
- W2890230728 doi "https://doi.org/10.1016/j.jtho.2018.09.001" @default.
- W2890230728 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6309637" @default.
- W2890230728 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30205166" @default.
- W2890230728 hasPublicationYear "2019" @default.
- W2890230728 type Work @default.
- W2890230728 sameAs 2890230728 @default.
- W2890230728 citedByCount "82" @default.
- W2890230728 countsByYear W28902307282019 @default.
- W2890230728 countsByYear W28902307282020 @default.
- W2890230728 countsByYear W28902307282021 @default.
- W2890230728 countsByYear W28902307282022 @default.
- W2890230728 countsByYear W28902307282023 @default.
- W2890230728 crossrefType "journal-article" @default.
- W2890230728 hasAuthorship W2890230728A5005314279 @default.
- W2890230728 hasAuthorship W2890230728A5005596596 @default.
- W2890230728 hasAuthorship W2890230728A5032331306 @default.
- W2890230728 hasAuthorship W2890230728A5037376490 @default.
- W2890230728 hasAuthorship W2890230728A5055464555 @default.
- W2890230728 hasAuthorship W2890230728A5064382279 @default.
- W2890230728 hasAuthorship W2890230728A5071789339 @default.
- W2890230728 hasAuthorship W2890230728A5072389805 @default.
- W2890230728 hasAuthorship W2890230728A5080311196 @default.
- W2890230728 hasAuthorship W2890230728A5081227348 @default.
- W2890230728 hasAuthorship W2890230728A5085217465 @default.
- W2890230728 hasBestOaLocation W28902307281 @default.
- W2890230728 hasConcept C121608353 @default.
- W2890230728 hasConcept C126322002 @default.
- W2890230728 hasConcept C143998085 @default.
- W2890230728 hasConcept C2776232967 @default.
- W2890230728 hasConcept C2776256026 @default.
- W2890230728 hasConcept C2777701055 @default.
- W2890230728 hasConcept C2779422266 @default.
- W2890230728 hasConcept C2780851360 @default.
- W2890230728 hasConcept C502942594 @default.
- W2890230728 hasConcept C71924100 @default.
- W2890230728 hasConceptScore W2890230728C121608353 @default.
- W2890230728 hasConceptScore W2890230728C126322002 @default.
- W2890230728 hasConceptScore W2890230728C143998085 @default.
- W2890230728 hasConceptScore W2890230728C2776232967 @default.
- W2890230728 hasConceptScore W2890230728C2776256026 @default.
- W2890230728 hasConceptScore W2890230728C2777701055 @default.
- W2890230728 hasConceptScore W2890230728C2779422266 @default.
- W2890230728 hasConceptScore W2890230728C2780851360 @default.
- W2890230728 hasConceptScore W2890230728C502942594 @default.
- W2890230728 hasConceptScore W2890230728C71924100 @default.
- W2890230728 hasFunder F4320337351 @default.
- W2890230728 hasIssue "1" @default.
- W2890230728 hasLocation W28902307281 @default.
- W2890230728 hasLocation W28902307282 @default.
- W2890230728 hasLocation W28902307283 @default.
- W2890230728 hasOpenAccess W2890230728 @default.
- W2890230728 hasPrimaryLocation W28902307281 @default.
- W2890230728 hasRelatedWork W1981099142 @default.
- W2890230728 hasRelatedWork W2146008341 @default.
- W2890230728 hasRelatedWork W2244308256 @default.
- W2890230728 hasRelatedWork W2516942920 @default.
- W2890230728 hasRelatedWork W2980533584 @default.
- W2890230728 hasRelatedWork W2983232492 @default.
- W2890230728 hasRelatedWork W3031100919 @default.
- W2890230728 hasRelatedWork W3035529108 @default.
- W2890230728 hasRelatedWork W3191746882 @default.
- W2890230728 hasRelatedWork W3197633853 @default.
- W2890230728 hasVolume "14" @default.
- W2890230728 isParatext "false" @default.
- W2890230728 isRetracted "false" @default.
- W2890230728 magId "2890230728" @default.
- W2890230728 workType "article" @default.